{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:30:46Z","timestamp":1780122646196,"version":"3.54.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Anthracycline (doxorubicin) and trastuzumab treatments for cancer patients have been known to cause cardiotoxicity. The current recommendations for prevention of cardiac events from cancer chemotherapies are largely based on opinion. The American Society of Clinical Oncology recommends active screening and prevention of modifiable cardiovascular risk factors. The risk factors are defined as tobacco use, high blood pressure, high cholesterol, alcohol use, obesity, and physical inactivity. Beta-adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors\/angiotensin receptor blockers (ARBs) have been the mainstay of treatment for heart failure patients with reduced left ventricular ejection fraction for many years. This review analyzed the use of beta-adrenergic blockers and ACE inhibitors\/ARBs as protection against cardiomyopathy caused by anthracyclines and trastuzumab. Although many more studies are warranted, it was concluded that the addition of a beta-blocker early in the treatment of cancer patients who are undergoing anthracycline or trastuzumab treatment can have beneficial effects in preserving left ventricular ejection fraction and preventing chemotherapy-induced cardiotoxicity. The effects are more apparent in the short term. More studies of the long-term effects are warranted, as are the additive effects of using a beta-blocker and ACE inhibitor\/ARB together to prevent chemotherapy-induced cardiotoxicity.<\/jats:p>","DOI":"10.1097\/crd.0000000000000252","type":"journal-article","created":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T01:43:29Z","timestamp":1555724609000},"page":"256-259","source":"Crossref","is-referenced-by-count":38,"title":["The Preventive Role of Angiotensin Converting Enzyme Inhibitors\/Angiotensin-II Receptor Blockers and \u03b2-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity"],"prefix":"10.1097","volume":"27","author":[{"given":"Julia B.","family":"Blanter","sequence":"first","affiliation":[{"name":"Department of Medicine Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College\/Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5301\/tj.5000507","article-title":"The roots of modern oncology: from discovery of new antitumor anthracyclines to their clinical use.","volume":"2016","author":"Cassinelli","year":"2016","journal-title":"Tumori"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice.","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.soncn.2017.08.010","article-title":"The role of cardio-oncology in the interprofessional care of adult patients receiving cancer therapy.","volume":"33","author":"Pituskin","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"R5-20230903","first-page":"47","article-title":"A review of heart failure treatment.","volume":"71","author":"Guyatt","year":"2004","journal-title":"Mt Sinai J Med"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.amjmed.2008.06.025","article-title":"Fifty years of beta-adrenergic blockade: a golden era in clinical medicine and molecular pharmacology.","volume":"121","author":"Frishman","year":"2008","journal-title":"Am J Med"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch Toxicol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/01.CIR.0000085166.44904.79","article-title":"Natural history of asymptomatic left ventricular systolic dysfunction in the community.","volume":"108","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cjca.2016.01.028","article-title":"Prevention, detection, and management of chemotherapy-related cardiac dysfunction.","volume":"32","author":"Abdel-Qadir","year":"2016","journal-title":"Can J Cardiol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/CRD.0000000000000225","article-title":"Cardiovascular effects of chemotherapy used in the treatment of breast cancers.","volume":"27","author":"Rozner","year":"2019","journal-title":"Cardiol Rev"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MPH.0000000000001118","article-title":"Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review.","volume":"40","author":"Liesse","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy.","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1124\/jpet.115.225375","article-title":"Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy.","volume":"355","author":"Chen","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","article-title":"Preventive role of carvedilol in adriamycin-induced cardiomyopathy.","volume":"144","author":"Jhorawat","year":"2016","journal-title":"Indian J Med Res"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.amjcard.2018.08.039","article-title":"Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity.","volume":"122","author":"Kheiri","year":"2018","journal-title":"Am J Cardiol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial.","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","article-title":"Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.","volume":"7","author":"Viani","year":"2007","journal-title":"BMC Cancer"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1080\/21645515.2015.1125056","article-title":"Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?","volume":"12","author":"Riccio","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jamaoncol.2016.0283","article-title":"Cardiac protection in HER2-targeted treatment: how should we measure new strategies?","volume":"2","author":"Barac","year":"2016","journal-title":"JAMA Oncol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial.","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity.","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ahj.2017.03.010","article-title":"Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: a rationale and design of a randomized clinical trial.","volume":"188","author":"Guglin","year":"2017","journal-title":"Am Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:13:10Z","timestamp":1693732390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000252","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}